


adjusted diluted earnings per share from continuing operations ^{(a) (b)}



quarterly, fiscal 2013 to present



| Fiscal Year | 1Q | 2Q | 3Q | 4Q | Year ^(d) |
|---------------------|---------|---------|---------|---------|---------------------|
| 2017 ^(c) | \$ 1.21 | \$ 1.23 | \$ 0.91 | \$ 1.37 | \$ 4.71 |
| 2016 | \$ 1.29 | \$ 1.23 | \$ 1.04 | \$ 1.45 | \$ 5.01 |
| 2015 | \$ 1.10 | \$ 1.22 | \$ 0.86 | \$ 1.52 | \$ 4.69 |
| 2014 ^(e) | \$ 0.92 | \$ 1.01 | \$ 0.79 | \$ 1.49 | \$ 4.22 |
| 2013 ^(e) | \$ 1.03 | \$ 1.16 | \$ 0.81 | \$ 1.29 | \$ 4.29 |

^(a) Adjusted diluted earnings per share from continuing operations ("Adjusted EPS"), a non-GAAP financial measure, excludes the impact of certain matters not related to the Company's single segment, such as losses on the early retirement of debt, discrete impacts of the Tax Cuts and Jobs Act, charges and other financial impacts related to the December 2015 sale of the pharmacy and clinic businesses to CVS, and the impact of certain other discretely managed items. The Company's financial releases include a reconciliation of non-GAAP to GAAP measures.

^(b) Diluted earnings per share includes the incremental shares assumed to be issued upon the exercise of stock options and the incremental shares assumed to be issued under performance share and restricted stock unit arrangements.

^(c) The fourth quarter and full year 2017 consisted of 14 weeks and 53 weeks, respectively, compared with 13 weeks and 52 weeks in the comparable prior-year periods.

^(d) Earnings per share was computed independently for each of the periods presented; therefore the sum of the earnings per share amounts for the quarters may not equal the total for the year.

^(e) 2013 and 2014 results have been restated to include amortization of the beneficial interest asset in Segment SG&A.

Source: Target's Consolidated Financial Statements as filed with the U.S. Securities and Exchange Commission.